Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 11-16 of 16

Page
per page
  1. 1-Naphthyl PP1
    A8605 1-Naphthyl PP1
    Summary: Src family kinases inhibitor
      ≥25.32 mg/mL
  2. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  3. PPY A
    A8607 PPY A
    Target: Abl kinases
    Summary: Abl kinases inhibitor
      <37.24 mg/mL
  4. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  5. Bafetinib (INNO-406)
    B1011 Bafetinib (INNO-406)
     2 Citation
    Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor
      ≥57.7 mg/mL
  6. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL

Items 11-16 of 16

Page
per page